Progyny's shares fell 9.3% after issuing Q1 earnings guidance below analyst estimates.
Progyny, a fertility benefits solutions provider, saw its shares fall 9.3% after issuing first-quarter earnings guidance of $0.12-0.13 EPS and revenue guidance of $285-292M, both below analyst estimates. The company's fiscal year 2024 guidance is now $0.66-0.71 EPS. Despite the setback, key analysts maintain a positive outlook with an average rating of Buy and a consensus target price of $48.60.
February 27, 2024
5 Articles